Philippe Steg
Declaration of interest
| Function | Company |
|---|---|
| None |
Latest contributions
Controversies in antiplatelet therapy for secondary prevention of coronary artery events
26 Jun 2020 – From PCR e-Course
Watch this session if you want to understand more about the guidelines for antiplatelet secondary prevention of ACS/PC and to review available data on antiplatelet therapy after ACS/PCI.
Pharmacological treatment of SARS-CoV2: ongoing and planned clinical trials
25 Jun 2020 – From PCR e-Course 2020
In this video, Philippe Gabriel Steg provides an in-depth review of ongoing and planned clinical trials for the pharmacological treatment of SARS-CoV2 (COVID-19), as well as discussing some of the challenges linked to these trials, particularly the methodological challenges: enrollment window, ethical questions, which outcomes to...
PCR Spotlight: COVID-19 - planned and ongoing trials
02 Jun 2020
Interventional Cardiologists P. G. Steg, Paris, France, and W. Wijns, Galway, Ireland, discuss the planned and ongoing trials related to COVID-19
Reducing long term ischaemic events in high-risk patients: the role of intensified antithrombotic treatment
23 May 2019 – From EuroPCR 2019
Consult this session to learn more about the role of intensified antithrombotic treatment in improving cardiovascular outcomes in high-risk patients and how to implement this treatment.
What every interventional cardiologist should know about new cardiovascular drugs
23 May 2019 – From EuroPCR 2019
Consult this session to learn all about the impact of new cardiovascular drugs in patients with coronary artery disease, diabetes and other high-risk conditions, such as PCSK9 and SGLT-2 inhibitors, GLP1 agonists, and more!
What every interventional cardiologist should know about new cardiovascular drugs
22 May 2019 – From EuroPCR 2019
Consult this session to learn all about the major impact of several new cardiovascular drugs in patients with coronary artery disease, diabetes and other high-risk conditions, such as PCSK9, DAPT, and more!
Cardiovascular outcomes of SGLT-2 inhibitors and GLP-1 agonists in patients with diabetes and coronary artery disease
22 May 2019 – From EuroPCR 2019
Consult this session to learn more about the cardiovascular outcomes of SGLT-2 inhibitors and GLP-1 agonists in patients with diabetes and coronary artery disease, and the clinical strategy for treatment implementation.
